Molecular Therapy Oncolytics-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-05-16 PSYoung

请问投了两周，仍然manuscript received，状态一直没变，是什么情况

106 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-01-15 wsasdeffgcf

偏重的研究方向：肿瘤
经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛

96 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-06-15 1881ff0ef5m

审稿速度:12.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。
这是最后的拒稿信：
Dear Dr. Fei,

Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration.

Best regards,

Yuman Fong, PhD
Editor-in-Chief, Molecular Therapy - Oncolytics

这是投稿时间线事件：
Jun 13, 2022 Editor Decision - Reject for History of Concerns
Jun 13, 2022 Author Submits Revision Confirmation
Jun 13, 2022 PDF Built and Requires Approval
Jun 09, 2022 Editor Decision - Pre-accept
May 18, 2022 Author Submits Revision Confirmation
May 18, 2022 PDF Built and Requires Approval
Mar 08, 2022 Editor Decision - Minor Revision
Oct 26, 2021 PDF Built and Requires Approval
Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship
Oct 25, 2021 PDF Built and Requires Approval
Oct 25, 2021 Sent Back to Author Notice
Oct 25, 2021 Author Notice of Manuscript Number
Oct 25, 2021 PDF Built and Requires Approval

112 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-08-06 小鬼鬼

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：基础
经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review
7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。
审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。

86 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-04-17 148030efm04暂无昵称

投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用

87 0

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-04-14 123925dfm05暂无昵称

请问要提供原始数据吗？

114 0

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-02-08 wsasdeffgcf

偏重的研究方向：肿瘤
经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了

94 0

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-10-26 alks

投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。

115 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-04-10 zhouxingzhi0329_32785698

偏重的研究方向：医学
经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上

120 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=966034, encodeId=92f7966034bb, content=请问投了两周，仍然manuscript received，状态一直没变，是什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=106, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a60c2049419, createdName=PSYoung, createdTime=Sun May 16 16:00:13 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184595, encodeId=6a301184595fa, content=偏重的研究方向：肿瘤 经验分享：with editor快半个月了，这状态是还在编辑手中吗?可以催稿嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Sat Jan 15 15:46:32 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226539, encodeId=168d122653950, content=审稿速度:12.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：分享一下这个杂志投稿，前后总共经历8个月，已经Pre-accept了，最后收到拒稿邮件，理由是他们审查到通讯作者之前有一篇被撤稿的文章，因此对这个文章的真实性产生了怀疑，属于株连九族的做法，撤稿的文章的作者和我这一篇的作者完全是两个团队，就因为导师是同一个所以就把我的文章给拒了，关键是来回8个月简直恶心。所以大家文章里如果有撤稿历史的作者，还是别投这个杂志了。 这是最后的拒稿信： Dear Dr. Fei, Thank you for submitting your revised paper. However, we have removed this paper from consideration for publication in MTO because we have become aware of image manipulation and duplication in some of your other published papers, as well as retractions and concerns on PubPeer. Since we are not confident in the authenticity and validity of your paper, we have withdrawn your paper from further consideration. Best regards, Yuman Fong, PhD Editor-in-Chief, Molecular Therapy - Oncolytics 这是投稿时间线事件： Jun 13, 2022 Editor Decision - Reject for History of Concerns Jun 13, 2022 Author Submits Revision Confirmation Jun 13, 2022 PDF Built and Requires Approval Jun 09, 2022 Editor Decision - Pre-accept May 18, 2022 Author Submits Revision Confirmation May 18, 2022 PDF Built and Requires Approval Mar 08, 2022 Editor Decision - Minor Revision Oct 26, 2021 PDF Built and Requires Approval Oct 26, 2021 Immediate Action Required-Unconfirmed Authorship Oct 25, 2021 PDF Built and Requires Approval Oct 25, 2021 Sent Back to Author Notice Oct 25, 2021 Author Notice of Manuscript Number Oct 25, 2021 PDF Built and Requires Approval , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a62141870, createdName=1881ff0ef5m, createdTime=Wed Jun 15 08:51:13 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236958, encodeId=f26c123695868, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：基础 经验分享：文章2022-08-02接收了，时间线如下：投稿MT被要求转投，2022.2.9同意转投，2.23 Under Review, 3.18 Under Review ，4.15修回，Major revision， 6.28 修回稿件，with editor；7.5：under review； 7.12 under review 7.15 Decision in Process 7.19 pre-accept (Revise) 7.27修回格式后提交 7.28 With Editor。 审稿真的非常慢。是大修，但是其实改动很少，两个审稿人，1个提了一些意见，补了一点点实验；另一个直接说可以接收，修回还是非常友好的，在截止时间线提前1个多月就修回去了。修回之后竟然还要提交给编辑，好吧，还是慢，3周才预接收。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c47f1644459, createdName=小鬼鬼, createdTime=Sat Aug 06 18:25:41 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211953, encodeId=64501211953d0, content=投稿到接受差不多5，6个月，初审3个月后大修，返修后半个月接收。希望能有参考作用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a555261630, createdName=148030efm04暂无昵称, createdTime=Sun Apr 17 17:46:11 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211212, encodeId=f28912112125c, content=请问要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77932419466, createdName=123925dfm05暂无昵称, createdTime=Thu Apr 14 18:44:59 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191071, encodeId=ca1511910e19d, content=偏重的研究方向：肿瘤 经验分享：1.4号投稿，一直是with editor 状态，2.6号发了一封邮件询问进展未回，2.7日更新状态变成under review了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab581969258, createdName=wsasdeffgcf, createdTime=Tue Feb 08 16:24:40 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063941, encodeId=55731063941c4, content=投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：这个期刊的编辑部里面的编辑都是尸体吗？1个多月了还是with editor，发邮件让他们撤稿，他们也不回，真是绝了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=581e2447283, createdName=alks, createdTime=Tue Oct 26 01:56:14 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955618, encodeId=5cfd95561899, content=偏重的研究方向：医学 经验分享：投稿1个多月一直是with editor，给编辑发邮件无任何回应，查了查类似的文章，最快需要4个月，最慢有9个月以上, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2289198, createdName=zhouxingzhi0329_32785698, createdTime=Sat Apr 10 05:44:46 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106907, encodeId=d2ec110690e0c, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:53 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 Mia

审稿人会不会通过我提供的关键词检索创新性？

101 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务